Anika Therapeutics, a developer of therapeutic products for tissue protection, healing and repair, has reported revenues of $13.9m for the third quarter of 2010, an increase of 29%, compared to $10.8 for the third quarter of 2009.
Anika Therapeutics posted a net income of $1.18m for the third quarter 2010, or 0.09 per diluted share, compared to net income of $1.51, or $0.13 per diluted share, for the comparable period in 2009.
Anika Therapeutics has posted an operating income of $2.07 for the third quarter 2010, compared to $2.01 for the comparable period in 2009.
For the nine months ended 30 September 2010, Anika Therapeutics’ revenues were $40.8m, compared to $29.5m for the year 2009.
Anika Therapeutics posted a net income of $2.96m, or $0.22 per diluted share, compared to $2.99m, or $0.26 per diluted share, for the year 2009.
Operating income was $5.05, compared to $3.98 for the same period in year 2009.
President and CEO Charles Sherwood said that Anika continued to perform well in the third quarter and driven by domestic sales of Orthovisc, it was their 13th consecutive quarter of year-over-year product revenue growth, and they advanced in ways on their key goals.